Key Outcome of HCV Trial: BIT225 Was safe and Well-Tolerated | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Drug Candidate Emricasan to Stop Progression of Liver Disease

Back to News Homepage
Next

Acupuncture + Curcumin = Potent Duo for Liver Health

Key Outcome of HCV Trial: BIT225 Was Safe and Well-Tolerated

The Editors at Hepatitis Central
March 18, 2016

Print this page

Find out why BIT225 might potentially be used in combination with new Hepatitis C drugs to help shorten treatment times and improve treatment outcomes.
Pin it on Pinterest

Biotron Phase 2 Hepatitis C Trial Success

March 17, 2016

PRNewswire — Biotron Limited (ASX: BIT) confirms positive outcomes from its Phase 2 study of its first-in-class antiviral drug BIT225.

The trial was designed to assess the safety and antiviral activity of three month’s dosing of BIT225 in patients infected with Hepatitis C virus (HCV). In addition, the trial provided key information on a new capsule form of BIT225, information that is critical for determining dosage in further studies with the drug.

Continue reading this entire article:
http://www.prnewswire.com/news-releases/biotron-phase-2-hepatitis-c-trial-success-300237625.html

2 Comments
Share
Share
Previous

Drug Candidate Emricasan to Stop Progression of Liver Disease

Back to News Homepage
Next

Acupuncture + Curcumin = Potent Duo for Liver Health

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.